Aoxing Pharmaceutical Company, Inc. announced unaudited consolidated earnings results for the first quarter ended September 30, 2015. For the quarter, the company announced net income of $1.35 million, or $0.02 per basic and diluted share, compared to a net loss of $2,405 for the same period last year. Revenues for the quarter jumped 92% to $8.7 million from $4.56 million reported a year ago.

The company attributed the revenue growth to a higher proportion of direct product sales made to its end customers, allowing for higher gross margins. The increased revenue was also a result of procurement from four provincial governments of the company's lead TCM product, Zhongtongan. Income from operations was $3,139,203 compared to $1,216,726 for the same period a year ago.

Profit before income tax was $2,292,236 compared to loss before income tax of $2,405 for the same period a year ago. Income attributable to shareholders of the company was $1,267,936 compared to loss attributable to shareholders of the company of $7,872 for the same period a year ago.